Lilly 3Q09 3Q Revenues: $5.6 billion (+7%) 3Q Earnings: $942 million (loss of $466 million in 3Q08) YTD Revenues: $15.9 billion (+5%) YTD Earnings: $3.4 billion (+119%) Comments: Earnings comparisons were affected by Lilly’s 3Q08 charge of $1.5 billion to settle federal and state investigations into Zyprexa marketing practices. U.S. revenues rose 14% to $3.1 billion, while ex-U.S. figures fell 1% to $2.4 billion. In 3Q09, Zyprexa revenues rose 3% to $1.2 billion, Cymbalta ro...